Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lantheus Holdings, Inc.

NASDAQ: LNTH · Life Sciences · 7 alerts · CIK 1521036

Share price
$101.72Close, Nov 16
Market cap
$6.65B
Shares outstanding
65.4MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lantheus Holdings, Inc. filings on SEC EDGAR ↗

6:00 AM ET 8-K
Divestiture

Lantheus Holdings Divestiture to PharmaLogic Holdings Corp.

Lantheus Holdings has entered into a definitive agreement to sell its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility to PharmaLogic. As part of the transaction, the parties will enter into a long-term supply agreement where PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus.

Counterparty
PharmaLogic Holdings Corp.
7:52 AM ET 10-Q
Financial Results

Lantheus Holdings Q3 2026 Results: Net Income $22.4M, Down 19.4% YoY

Lantheus Holdings reported net income of $215.8 million for the nine months ended September 30, 2026, compared to $179.5 million in the prior year period. The company saw a significant increase in cash and cash equivalents to $683.6 million, bolstered by a $59.4 million gain on the sale of a business.

Key figure
Net income $22.4M · -19.4% YoY
7:41 AM ET 8-K
Financial Results

Lantheus Holdings Financial Results

Lantheus Holdings reported Q3 2026 financial results with worldwide revenue of $389.9 million and adjusted EPS of $1.68. The company also highlighted the pending $8.0 billion acquisition by Curium and the recent FDA approvals of TAUKLARIFY and BRAVNETSA. Due to the pending merger, the company has suspended its full-year 2026 financial guidance.

7:30 AM ET 8-K
M&A Deal

Lantheus Holdings M&A Deal with Curium US Holdings LLC

Lantheus Holdings and Curium US Holdings received a 'Second Request' for information from the FTC regarding their pending merger agreement. This request extends the HSR Act waiting period, though both parties still expect the transaction to close in the first half of 2027.

Counterparty
Curium US Holdings LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.